AMSTERDAM: BenevolentAI (Euronext Amsterdam: BAI), a leader in AI-driven drug discovery, announced plans to delist from Euronext Amsterdam via a merger with Osaka Holdings S.à r.l., a private entity. This move, subject to shareholder approval, aims to simplify the company’s structure and reduce administrative overhead. Following an extensive review, the Board concluded that the costs…
Tag: BenevolentAI
BenevolentAI refocuses business strategy, cuts workforce by 30%
Amsterdam-based biopharma AI leader BenevolentAI announced a strategic shift to concentrate on AI-driven drug discovery and proprietary pipeline revenue streams. The decision follows the discontinuation of its Knowledge Exploration Tools due to high commercialization costs and a lengthy ROI timeline. This pivot is expected to enhance shareholder returns. The company will reduce its workforce by…
BenevolentAI appoints Dr. Joerg Moeller as new CEO
BenevolentAI, a leading AI-powered biopharma company, announced today that Dr. Joerg Moeller, a veteran in the pharmaceutical industry, has joined the company as its new CEO and Executive Board member. Dr. Joerg Moeller has over 20 years of experience in leading global R&D organisations and driving innovation and value creation. He has also been involved…
BenevolentAI announces strategic plan to boost AI and biopharma businesses
AMSTERDAM: BenevolentAI, a leader that combines cutting-edge Artificial Intelligence (AI) and science to accelerate biopharma discovery and development, today announced a strategic review approved by its Board of Directors. The Company said it is further evolving its differentiated technology platform and launching a new suite of products to capitalise on the vast potential of AI-driven…